{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Overall survival was to be estimated by the Kaplan-Meier method and arms were to be compared using a log-rank test. Analysis was to occur when at least 105 deaths had been reported. Given the small number of participants due to early study closure, only the number of patients last reported to be alive at time of study termination is reported.","groups":[{"description":"\\[Intent-to-treat\\]\n\nSTEP 1 (all patients): Patients who received allowed neoadjuvant systemic therapy before study entry undergo pleurectomy/decortication (P/D) within 4 to 8 weeks of systemic therapy. Otherwise, patients undergo P/D within 4 weeks of study entry followed within 4 to 8 weeks by four 21-day cycles of pemetrexed and cisplatin or carboplatin on day 1.\n\nSTEP 2 (randomized): Patients receive no treatment.","id":"OG000","title":"Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment)"},{"description":"\\[Intent-to-treat\\]\n\nSTEP 1 (all patients): Same as Arm 1.\n\nSTEP 2 (randomized): Within 4-8 weeks from the end of Step 1 treatment, patients undergo 25-28 fractions of intensity modulated radiation therapy (IMRT) or pencil beam scanning (PBS) proton therapy 5 days/week over 6 weeks.","id":"OG001","title":"Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomized patients","reportingStatus":"POSTED","timeFrame":"Randomization to the date of death or last follow-up. Maximum follow-up time from randomization was 25 months.","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Participants"}